| Literature DB >> 23028524 |
Pasha Grachev1, Xiao Feng Li, Yuan Shao Lin, Ming Han Hu, Leena Elsamani, Stewart J Paterson, Robert P Millar, Stafford L Lightman, Kevin T O'Byrne.
Abstract
Kisspeptin, neurokinin B (NKB) and dynorphin A (Dyn) are coexpressed within KNDy neurons that project from the hypothalamic arcuate nucleus (ARC) to GnRH neurons and numerous other hypothalamic targets. Each of the KNDy neuropeptides has been implicated in regulating pulsatile GnRH/LH secretion. In isolation, kisspeptin is generally known to stimulate, and Dyn to inhibit LH secretion. However, the NKB analog, senktide, has variously been reported to inhibit, stimulate or have no effect on LH secretion. In prepubertal mice, rats and monkeys, senktide stimulates LH secretion. Furthermore, in the monkey this effect is dependent on kisspeptin signaling through its receptor, GPR54. The present study tested the hypotheses that the stimulatory effects of NKB on LH secretion in intact rats are mediated by kisspeptin/GPR54 signaling and are independent of a Dyn tone. To test this, ovarian-intact prepubertal rats were subjected to frequent automated blood sampling before and after intracerebroventricular injections of KNDy neuropeptide analogs. Senktide robustly induced single LH pulses, while neither the GPR54 antagonist, Kp-234, nor the Dyn agonist and antagonist (U50488 and nor-BNI, respectively) had an effect on basal LH levels. However, Kp-234 potently blocked the senktide-induced LH pulses. Modulation of the Dyn tone by U50488 or nor-BNI did not affect the senktide-induced LH pulses. These data demonstrate that the stimulatory effect of NKB on LH secretion in intact female rats is dependent upon kisspeptin/GPR54 signaling, but not on Dyn signaling.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23028524 PMCID: PMC3460954 DOI: 10.1371/journal.pone.0044344
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Effect of NK3R agonist on LH secretion following pre-treatment with GPR54 antagonist.
Representative LH profiles demonstrating the effect of icv administration (long arrow) of a selective NK3R agonist, senktide (C, D, E), or vehicle (A, B) on pulsatile LH secretion in gonadal-intact prepubertal female rats in the presence (A, B, D, E; short arrows) or absence (C) of the selective GPR54 antagonist, Kp-234. Central administration of senktide induced a single LH pulse (C), while intermittent infusion of Kp-234 had no effect on basal LH levels (A, B). Kp-234 potently blocked senktide-induced LH pulses (D). Where spontaneous LH pulses (B, E) were detected during the pre-treatment period, these were excluded from analysis by comparing the previous 30-min period devoid of spontaneous LH pulses with the 30-min post-treatment period (B). Administration of Kp-234 immediately following a spontaneous LH pulse tended to attenuate the pulse (B), as compared to spontaneous LH pulses occurring considerably prior to Kp-234 administration, which were unaffected (E). The 30-min post-treatment period commenced at the time of the senktide/vehicle injection (long arrow). Area under the curve (AUC) values in the 30-min pre-treatment (baseline) period (AUC1) and the 30-min post-treatment period (AUC2) for the three treatment groups are compared in the experiment summary (F). *P<0.05 versus 30-min pre-treatment (baseline) period within the same treatment group, as well as versus the same 30-min period within the group treated with Kp-234 and senktide; n = 3−9 per group.
Figure 2Effect of NK3R agonist on LH secretion following pre-treatment with KOR agonist or antagonist.
Representative LH profiles demonstrating the effect of icv administration (long arrow) of a selective NK3R agonist, senktide (C, D), or vehicle (A, B) on pulsatile LH secretion in gonadal-intact prepubertal female rats in the presence (short arrows) of the selective KOR agonist, U50488 (A, C), or the selective KOR antagonist, nor-BNI (B, D). Central infusion of U50488 or nor-BNI had no effect on basal LH levels (A, B). Likewise, neither U50488, nor nor-BNI, affected the senktide-induced LH pulses (C, D). The 30-min post-treatment period commenced at the time of the senktide/vehicle injection (long arrow). Area under the curve (AUC) values in the 30-min pre-treatment (baseline) period () and the 30-min post-treatment period () for the five treatment groups are compared in the experiment summary (E). *P<0.05 versus 30-min pre-treatment (baseline) period within the same treatment group, as well as versus the same 30-min period within the group treated with U50488 and vehicle, and with nor-BNI and vehicle; n = 4−10 per group.